CareDx (NASDAQ:CDNA) used an investor webcast to outline its “Transplant Plus” expansion into cell therapy and to highlight ...
Panelists discuss how emerging therapies like menin inhibitors show promise based on strong preclinical data and clinical responses, while CD47 inhibitors have faced setbacks in phase 3 trials, with ...
Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...
AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting LYT-200 is generally safe and well-tolerated as a single agent ...
DNA methylation profiles in whole blood samples from 77 patients with CN-AML in The Cancer Genome Atlas (LAML cohort) were analyzed. Individual 5’-cytosine-phosphate-guanine-3’ (CpG) sites were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results